<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157647</url>
  </required_header>
  <id_info>
    <org_study_id>IMHeS</org_study_id>
    <nct_id>NCT04157647</nct_id>
  </id_info>
  <brief_title>Hemadsorption During and After Cardiopulmonary Bypass to Modulate the Inflammatory Response</brief_title>
  <acronym>IMHeS</acronym>
  <official_title>Monocentric Prospective Randomized Pilot Study in Patients With Kidney Failure to Evaluate the Relationship Between the Hemadsorption During and After Cardiopulmonary Bypass and the Modulation of Post-surgical Inflammatory Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Magna Graecia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Magna Graecia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) is a risk factor for the development of cardiovascular disease,
      which increases the risk of death after cardiac surgery. High interleukin 6 (IL-6) blood
      levels is commonly observed in patients with CKD, and this is particularly high after cardiac
      surgery. High IL-6 levels are also associated with increased long-term mortality rate after
      cardiac surgery. To date, the use of ultrafiltration or endotoxin adsorption systems were not
      found to improve the clinical outcome, although able to reduce the inflammatory mediators
      concentrations. In the last years, a new extracorporeal hemadsorption filter (CytoSorb) has
      been developed for removal of inflammatory cytokines and it has been approved by the European
      Union. However, data lack about the impact on clinical outcome of the use of CytoSorb in
      patients with CKD undergoing cardiac surgery with cardio-pulmonary bypass (CPB). The
      investigators have therefore designed this pilot prospective randomized trial to evaluate the
      efficacy the intraoperative use of CytoSorb for cytokines removal to prevent the inflammatory
      response associated with the cardiac surgery and complications in patients with CKD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IL-6 concentration at ICU admission</measure>
    <time_frame>At day 0 after surgery</time_frame>
    <description>Investigators will assess the blood IL-6 concentrations between the two arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IL-6 concentration before cardiac surgery</measure>
    <time_frame>At day 0 before the cardiac surgery</time_frame>
    <description>Investigators will assess the blood IL-6 concentrations between the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 concentration at the end of CardioPulmonary Bypass</measure>
    <time_frame>At day 0 at the end of the CardioPulmonary Bypass</time_frame>
    <description>Investigators will assess the blood IL-6 concentrations between the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 concentration 2 hours after the end of CardioPulmonary Bypass</measure>
    <time_frame>2 hours after the end of CardioPulmonary Bypass</time_frame>
    <description>Investigators will assess the blood IL-6 concentrations between the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 concentration 48 hours after the end of CardioPulmonary Bypass</measure>
    <time_frame>48 hours after the end of CardioPulmonary Bypass</time_frame>
    <description>Investigators will assess the blood IL-6 concentrations between the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>daily up to day 15</time_frame>
    <description>Investigators will assess the blood creatinine concentrations in the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myoglobin concentration</measure>
    <time_frame>daily up to day 15</time_frame>
    <description>Investigators will assess the blood myoglobin concentrations in the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haptoglobin concentration</measure>
    <time_frame>daily up to day 15</time_frame>
    <description>Investigators will assess the blood haptoglobin concentrations in the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver transaminases concentration</measure>
    <time_frame>daily up to day 15</time_frame>
    <description>Investigators will measure the liver transaminases concentrations in the two arms to assess any liver injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteopontin concentration</measure>
    <time_frame>daily up to day 15</time_frame>
    <description>Investigators will measure the osteopontin concentrations in the two arms to assess the inflammatory status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free hemoglobin concentration</measure>
    <time_frame>daily up to day 15</time_frame>
    <description>Investigators will assess the free hemoglobin concentrations in the two arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Inflammatory Response</condition>
  <condition>Chronic Renal Disease</condition>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>CytoSorb</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to this arm group will receive hemadsorption witbhCytoSorb during the surgery and in the next 24 hours after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients assigned to this arm group will undergo to a normal CPB without the use of any hemoadsorption system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb</intervention_name>
    <description>The hemadsorption filter will be included in the CPB circuit between the oxygenator and the venous reservoir. After cardiac surgery, the use of the filter will be continued till 24 hours after the end of surgery.</description>
    <arm_group_label>CytoSorb</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>No hemadsorption filter or other treatment will be included in the CPB circuit</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All consecutive adult patients (age &gt;65 years) undergoing cardiac surgery with an
             anticipated CPB time duration longer than 60 minutes.

          -  Presence of CKD defined by a Glomerular Filtration Rate (eGFR) &lt; 60 ml/min/1.73 m2.

          -  Consent to participate to the study

        Exclusion Criteria:

          -  emergency surgery

          -  acute infective endocarditis

          -  systemic infectious diseases

          -  previous kidney transplant

          -  need for contrast enhancement during surgery

          -  immunosuppressive or long-term corticosteroid therapies

          -  participation to other investigations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Serraino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Magna Graecia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe F Serraino, MD</last_name>
    <phone>0039 0961 3647033</phone>
    <email>filiberto@live.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>AOU Mater Domini</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006 Jul;17(7):2034-47. Epub 2006 May 31. Review.</citation>
    <PMID>16738019</PMID>
  </reference>
  <reference>
    <citation>Penta de Peppo A, Nardi P, De Paulis R, Pellegrino A, Forlani S, Scafuri A, Chiariello L. Cardiac surgery in moderate to end-stage renal failure: analysis of risk factors. Ann Thorac Surg. 2002 Aug;74(2):378-83.</citation>
    <PMID>12173816</PMID>
  </reference>
  <reference>
    <citation>Durmaz I, Büket S, Atay Y, Yağdi T, Ozbaran M, Boğa M, Alat I, Güzelant A, Başarir S. Cardiac surgery with cardiopulmonary bypass in patients with chronic renal failure. J Thorac Cardiovasc Surg. 1999 Aug;118(2):306-15.</citation>
    <PMID>10425004</PMID>
  </reference>
  <reference>
    <citation>Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003 Jun;41(6):1212-8.</citation>
    <PMID>12776273</PMID>
  </reference>
  <reference>
    <citation>Takahashi T, Kubota M, Nakamura T, Ebihara I, Koide H. Interleukin-6 gene expression in peripheral blood mononuclear cells from patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Ren Fail. 2000 May;22(3):345-54.</citation>
    <PMID>10843245</PMID>
  </reference>
  <reference>
    <citation>Caglar K, Peng Y, Pupim LB, Flakoll PJ, Levenhagen D, Hakim RM, Ikizler TA. Inflammatory signals associated with hemodialysis. Kidney Int. 2002 Oct;62(4):1408-16.</citation>
    <PMID>12234313</PMID>
  </reference>
  <reference>
    <citation>Corral-Velez V, Lopez-Delgado JC, Betancur-Zambrano NL, Lopez-Suñe N, Rojas-Lora M, Torrado H, Ballus J. The inflammatory response in cardiac surgery: an overview of the pathophysiology and clinical implications. Inflamm Allergy Drug Targets. 2015;13(6):367-70. Review.</citation>
    <PMID>26021321</PMID>
  </reference>
  <reference>
    <citation>de Amorim CG, Malbouisson LM, da Silva FC Jr, Fiorelli AI, Murakami CK, Carmona MJ. Leukocyte depletion during CPB: effects on inflammation and lung function. Inflammation. 2014 Feb;37(1):196-204. doi: 10.1007/s10753-013-9730-z.</citation>
    <PMID>24092406</PMID>
  </reference>
  <reference>
    <citation>Ilmakunnas M, Pesonen EJ, Ahonen J, Rämö J, Siitonen S, Repo H. Activation of neutrophils and monocytes by a leukocyte-depleting filter used throughout cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005 Apr;129(4):851-9.</citation>
    <PMID>15821654</PMID>
  </reference>
  <reference>
    <citation>Wiegele M, Krenn CG. Cytosorb™ in a patient with Legionella pneumonia-associated rhabdomyolysis: a case report. ASAIO J. 2015 May-Jun;61(3):e14-6. doi: 10.1097/MAT.0000000000000197.</citation>
    <PMID>25635933</PMID>
  </reference>
  <reference>
    <citation>Basu R, Pathak S, Goyal J, Chaudhry R, Goel RB, Barwal A. Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: A case study. Indian J Crit Care Med. 2014 Dec;18(12):822-4. doi: 10.4103/0972-5229.146321.</citation>
    <PMID>25538418</PMID>
  </reference>
  <reference>
    <citation>Hetz H, Berger R, Recknagel P, Steltzer H. Septic shock secondary to β-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy. Int J Artif Organs. 2014 May;37(5):422-6. doi: 10.5301/ijao.5000315. Epub 2014 Apr 17.</citation>
    <PMID>24811308</PMID>
  </reference>
  <reference>
    <citation>Vercaemst L. Hemolysis in cardiac surgery patients undergoing cardiopulmonary bypass: a review in search of a treatment algorithm. J Extra Corpor Technol. 2008 Dec;40(4):257-67. Review.</citation>
    <PMID>19192755</PMID>
  </reference>
  <reference>
    <citation>Kahles F, Findeisen HM, Bruemmer D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab. 2014 Mar 22;3(4):384-93. doi: 10.1016/j.molmet.2014.03.004. eCollection 2014 Jul. Review.</citation>
    <PMID>24944898</PMID>
  </reference>
  <reference>
    <citation>Baumann A, Buchwald D, Annecke T, Hellmich M, Zahn PK, Hohn A. RECCAS - REmoval of Cytokines during CArdiac Surgery: study protocol for a randomised controlled trial. Trials. 2016 Mar 12;17(1):137. doi: 10.1186/s13063-016-1265-9.</citation>
    <PMID>26971164</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Magna Graecia</investigator_affiliation>
    <investigator_full_name>GIUSEPPE FILIBERTO SERRAINO</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hemadsorption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The full protocol, datasets used and analysed during the current study will be available on reasonable request after study publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After scientific publication</ipd_time_frame>
    <ipd_access_criteria>On reasonable request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

